Company news
AbbVie Inc. news in 2025
AbbVie Inc.'s news releases, calls and decks from 2025, newest first.
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
December 14, 2025
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
December 8, 2025
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
December 2, 2025
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
November 28, 2025
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
November 25, 2025
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
November 18, 2025
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
November 17, 2025
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
November 14, 2025
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
November 13, 2025
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
November 12, 2025
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
November 12, 2025
Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease
November 5, 2025
AbbVie Reports Third-Quarter 2025 Financial Results
October 31, 2025
ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
October 30, 2025
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
October 29, 2025
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
October 28, 2025
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
October 21, 2025
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
October 17, 2025
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
October 13, 2025
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
October 13, 2025
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
October 9, 2025
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
October 6, 2025
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
October 2, 2025
Natrelle® Awarded Supplier Agreement from Vizient
October 1, 2025
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
September 30, 2025
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
September 30, 2025
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
September 29, 2025
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
September 29, 2025
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
September 26, 2025
QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
September 25, 2025
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
September 25, 2025
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
September 23, 2025
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
September 15, 2025
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
September 9, 2025
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
September 3, 2025
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 2, 2025
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
August 31, 2025
RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
August 27, 2025
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
August 25, 2025
AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
August 21, 2025
AbbVie Completes Acquisition of Capstan Therapeutics
August 19, 2025
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
August 12, 2025
Get Ready, JUVÉDERM® Day is Calling!
August 6, 2025
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
August 5, 2025
AbbVie Reports Second-Quarter 2025 Financial Results
July 31, 2025
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
July 30, 2025
AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
July 29, 2025
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
July 22, 2025
AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
July 15, 2025
Calls in 2025
Decks in 2025
- Q1 2025 Earnings Presentation
Earnings · 9 slides · Apr 25, 2025
- Fact Sheet (2025)
Fact sheet · 6 slides · 2025